{"id":"donepezil-hci-drug","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"6-8","effect":"Muscle cramps"},{"rate":"5-10","effect":"Fatigue"},{"rate":"6-10","effect":"Insomnia"},{"rate":"2-3","effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL502","moleculeType":"Small molecule","molecularWeight":"379.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By inhibiting this enzyme, donepezil increases acetylcholine concentration in the central nervous system, enhancing cholinergic neurotransmission. This mechanism helps improve memory, attention, and cognitive function in patients with Alzheimer's disease, particularly in early to moderate stages.","oneSentence":"Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:37:05.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Moderate to severe Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00315367","phase":"PHASE4","title":"A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties","status":"COMPLETED","sponsor":"Neurognostics","startDate":"2004-09","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Donepezil HCI (drug)","genericName":"Donepezil HCI (drug)","companyName":"Neurognostics","companyId":"neurognostics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease. Used for Mild to moderate Alzheimer's disease, Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}